22 December 2019 in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
Повторные резекции печени у больных колоректальным раком с метастазами
21 August 2026 in MD-Onco
Peritoneal carcinomatosis is one of the most unfavorable scenarios in the progression of malignant tumors and substantially worsens the prognosis in ovarian cancer, colorectal cancer, gastric cancer, pancreatic cancer, appendiceal tumors, and other oncological diseases. We reviewed current data on the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in combination with cytoreductive surgery for secondary peritoneal carcinomatosis associated with various malignant tumors. The results of several randomized trials and large observational studies suggest that HIPEC may improve survival, reduce the risk of recurrence, and enhance local disease control in selected groups of patients. The most convincing evidence has been obtained for ovarian, gastric, colorectal, pancreatic, and appendiceal malignancies. At the same time, the evidence base remains heterogeneous: the efficacy of HIPEC depends on the tumor type, disease extent, completeness of cytoreduction, chemotherapy regimen, and patient selection. Despite the accumulated clinical experience and a substantial body of evidence, representation of this technique in Russian clinical guidelines is still very limited. Further randomized studies could help generate more data on the efficacy of HIPEC and the specifics of its clinical application, accelerate its incorporation into Russian clinical protocols, thereby make it more accessible to patients with advanced-stage oncological diseases.
21 August 2026 in MD-Onco
Chemotherapy-associated nausea and vomiting remain one of the most significant problems in oncology despite development of modern antiemetics. These symptoms decrease patients’ quality of life and treatment compliance and can lead to clinically significant complications including dehydration, electrolyte imbalances, and modification of antitumor therapy. Pathogenesis of chemotherapy-associated nausea and vomiting is multifactorial and includes activation of both peripheral and central mechanisms, with key being serotoninergic and neuroendocrine NK1 receptors. This underlies the necessity of using combination antiemetic therapy directed at various parts of vomiting reflex pathogenesis. Modern clinical guidelines make provisions for multicomponent schemes, but their efficacy is limited by low patient adherence and development of adverse effects. Netupitant and palonosetron combination (NEPA) is a mixture of NK1 receptor antagonist and 5-HT3 receptor antagonist which affect the key mechanisms of chemotherapy-associated nausea and vomiting. Pharmacokinetic characteristics of the components allow to use the drug once prior to administration of chemotherapy in combination with dexamethasone which makes therapy more comfortable and increase patients’ compliance. According to randomized clinical trials, NEPA demonstrates high efficacy in prevention of both acute and delayed chemotherapy-associated nausea and vomiting during moderately and highly emetogenic chemotherapies leading to high rates of complete remission and similar or more favorable safety profile compared to the standard of care. Additional benefits include lower need for salvage therapy and potentially lower treatment costs. Therefore, the use of NEPA combination is a justified and effective approach to prevention of chemotherapy-associated nausea and vomiting and allows to optimize antiemetic therapy through increased efficacy, safety and treatment adherence.